Drug recall: CellCept (mycophenolate mofetil) capsules, 250 mg, packaged in a) 12 x 120-count bottles per carton, NDC 0004-0259-05; b

FDA enforcement event 63874 · Class III · initiated 27 Sep 2012 · status Terminated · terminated 20 Nov 2014

DrugVoluntary: Firm initiated1 product recordSouth San Francisco, CA

FDA enforcement event 63874 is a drug recall by Genentech, Inc. of South San Francisco, CA, initiated 27 Sep 2012 and classified Class III, with 1 product record.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 28% of the 209 drug enforcement events initiated in 2012 carry the same class.

Status: Terminated, terminated 20 Nov 2014. Initiation: voluntary: firm initiated. Genentech, Inc. has 10 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Genentech, Inc., South San Francisco, CA.

Reason for recall

"Short Fill: some bottles contained less than 120-count per labeled claim."

Distribution

"Nationwide"

Product records

Recall number	Product	Quantity	Class	Status	Report date
D-097-2013	CellCept (mycophenolate mofetil) capsules, 250 mg, packaged in a) 12 x 120-count bottles per carton, NDC 0004-0259-05; b) 120-count capsules per bottle, NDC 0004-0259-51; Made in Ireland; Distributed by: Genentech USA, Inc., South San Francisco, CA 94080.	1128 bottles	Class III	Terminated	26 Dec 2012

Context

28%of 2012 drug events are Class III209 events that year

1product record in this eventfirm median: 1

10events on this register for the firm

Other enforcement events for Genentech, Inc.

Initiated	Product (first record)	Type	Class	Records
20 May 2024	Cathflo activase (ALTEPLASE), 2mg vials, Rx only, Genentech Inc., South San Francisco, CA 94080, NDC 50242-041-64	Drug	Class II	1
18 Oct 2022	Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Su	Drug	Class III	1
9 Jun 2021	Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Sy	Drug	Class II	1
20 Apr 2021	Evrysdi (risdiplam) for oral solution, 60 mg/80mL (0.75mg/mL), 80 mL total volume after constitution, Rx only, Distribut	Drug	Class III	1
5 Feb 2018	Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Mem	Drug	Class III	1
5 Sep 2017	Activase (alteplase), 100 mg (58 million IU), Lyophilized vial, packaged with 1 single-dose 100ml vial of sterile water	Drug	Class I	1
13 Mar 2017	Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc.	Drug	Class II	1
20 Sep 2012	Nutropin AQ NuSpin 20 (somatropin (rDNA origin) injection} 20 mg/ 2mL Genentech, South San Francisco, CA 94080, NDC#5024	Drug	Class II	2
30 Jul 2012	Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vial Bacteriostatic Water	Drug	Class I	1

All 10 events for Genentech, Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Short Fill: some bottles contained less than 120-count per labeled claim."

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 20 Nov 2014. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.